Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
No 8-K events recorded for this window.
Oscar Health grew second-quarter revenue 70% year-over-year to $4.9 billion as membership rose 46% to 2.96 million, and earnings from operations swung to $389 million, a $619 million improvement, with net income of $362 million. The medical loss ratio improved nearly 12 points to 79.2%, helped by $164 million of favorable prior period development that included a roughly $160 million favorable final 2025 risk adjustment report, while the SG&A expense ratio fell 450 basis points to a record low of 14.2% on expense discipline and AI-driven efficiencies. Management raised full-year 2026 earnings from operations guidance by $250 million to $500 million to $700 million, improved its MLR outlook to 81.5% to 82.5%, and kept total revenue guidance at $18.7 billion to $19 billion. The ACA market is down 12% to 19.2 million lives but tracking favorable to pricing assumptions, and management expects MLR to rise seasonally and back-half churn to roughly double as CMS eligibility reviews continue.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $2.39B | +67.1% | -$0.62 | — | -6.2% | -6.4% | $340M |
| FY2025 Q1 | $3.05B | +42.2% | $0.92 | +48.4% | 9.8% | 9.0% | $870M |
| FY2025 Q2 | $2.86B | +29.0% | -$0.89 | -545.0% | -8.0% | -8.0% | $500M |
| FY2025 Q3 | $2.99B | +23.2% | -$0.53 | n/m | -4.3% | -4.6% | -$974M |
| FY2025 Q4 | $2.81B | +17.3% | -$1.24 | n/m | -11.9% | -12.6% | $663M |
| FY2026 Q1 | $4.65B | +52.6% | $2.07 | +125.0% | 15.2% | 14.6% | $2.61B |
| FY2026 Q2Selected | $4.88B | +70.4% | $1.10 | n/m | 8.0% | 7.4% | $2.08B |
| FY2026 Q3 | $5.14B | +72.1% | $0.49 | n/m | 3.5% | 3.3% | -$1.21B |
FY2025 Q3: Prior-year quarter was a loss (-$0.22 EPS), so a percent change isn't meaningful.
Margin | Regulation Policy | Subscriber Growth | Pricing | Cost Pressure | Competitive Dynamics | Guidance Reliability | Product Launch | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 7 | 3 | 4 | 1 | 2 | 1 | 2 | |
| 2025Q1 | 5 | 8 | 5 | 4 | 2 | 2 | 1 | |
| 2025Q2 | 5 | 7 | 1 | 6 | 3 | 3 | 1 | |
| 2025Q3 | 7 | 6 | 4 | 6 | 3 | 3 | 1 | |
| 2025Q4 | 9 | 2 | 10 | 3 | 1 | 2 | 3 | 2 |
| 2026Q1 | 5 | 6 | 4 | 1 | 4 | 2 | 3 | 1 |
| 2026Q2 | 8 | 7 | 6 | 2 | 5 | 2 | 5 | 3 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | '26Q2 | |
|---|---|---|---|---|---|---|---|
| Margin | 7 | 5 | 5 | 7 | 9 | 5 | 8 |
| Regulation Policy | 3 | 8 | 7 | 6 | 2 | 6 | 7 |
| Subscriber Growth | 4 | 5 | 1 | 4 | 10 | 4 | 6 |
| Pricing | 1 | 4 | 6 | 6 | 3 | 1 | 2 |
| Cost Pressure | 2 | 2 | 3 | 3 | 1 | 4 | 5 |
| Competitive Dynamics | 1 | 2 | 3 | 3 | 2 | 2 | 2 |
| Guidance Reliability | 2 | 1 | 1 | 3 | 3 | 5 | |
| Product Launch | 1 | 2 | 1 | 3 |
FY2025 Q4: Prior-year quarter was a loss (-$0.62 EPS), so a percent change isn't meaningful.
FY2026 Q2: Prior-year quarter was a loss (-$0.89 EPS), so a percent change isn't meaningful.
FY2026 Q3: Prior-year quarter was a loss (-$0.53 EPS), so a percent change isn't meaningful.
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Calendar quarter Q2 2026Earnings call Aug 6, 2026
FY2026 Q2 in brief
Oscar Health grew second-quarter revenue 70% year-over-year to $4.9 billion as membership rose 46% to 2.96 million, and earnings from operations swung to $389 million, a $619 million improvement, with net income of $362 million.
Newest scored quarter FY2026 Q3 is part of Pro · see what Pro adds →
GAAP revenue YoY +70.4% → base 8. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
Sources. Tellvest earnings-call sentiment score for Oscar Health, Inc. (OSCR), FY2026 Q2: 10/10. Scores: Oscar Health, Inc.’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: OSCR daily prices (open, high, low, close) with a 50-day moving average; lines mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
Mentions of other companies on OSCR's FY2026 Q2 call, and mentions of OSCR on other companies' calls covering the same calendar quarter (Q2 2026). Each company's own fiscal quarter is shown next to its name. Extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“ICHRAx is then connected to Lucie where we are now starting to have -- we have Allstate Health.”
Oscar's CEO named Allstate Health among the first companies on its Lucie retail platform, giving it access to Oscar's individual-market members.
“We have Aflac. We have a lot of retailers that want to get access to our members.”
Oscar's CEO named Aflac among companies joining its Lucie retail platform to reach Oscar members, a new distribution channel for Aflac's supplemental products.
“Wakely's first claim-based report of 2026 market morbidity is also favorable to our expectations, suggesting potential upside to our outlook.”
Oscar's CEO said Wakely's first claims-based report on 2026 ACA market morbidity came in favorable to expectations, showing how insurers lean on Wakely data to set risk adjustment accruals.
| Company | Score | Trend | Rev YoY | Headline |
|---|---|---|---|---|
| OSCROscar Health, Inc. | 10 | +70.4% | Oscar Health grew second-quarter revenue 70% year-over-year to $4.9 billion as membership rose 46% to 2.96 million, and earnings from operations swung to $389 million, a $619 million improvement, with net income of $362 million | |
| CICigna | 8 | +6.7% | The Cigna Group delivered total revenues of $71.7 billion and adjusted EPS of $7.78, with both Evernorth and Cigna Healthcare coming in ahead of expectations | |
| CNCCentene Corporation | 9 | +9.9% | Centene reported $44.4 billion in premium and service revenue and adjusted diluted earnings per share of $2.51, with the consolidated health benefits ratio falling to 89.6% from 93% a year earlier | |
| CVSCVS Health | 9 | +7.3% | CVS Health delivered a broad-based beat, with revenue up 7.26% to over $106 billion and GAAP operating income up 97.5% year over year as every operating segment grew earnings | |
| ELVElevance Health | 5 | +1.4% | Elevance Health delivered adjusted diluted EPS of $7.45, ahead of its outlook, and raised full-year 2026 adjusted EPS guidance to at least $27 on favorable Medicare Advantage and individual ACA benefit-expense performance and disciplined execution | |
| HUMHumana | 8 | +26.2% | Humana grew GAAP revenue 26.18% year over year on membership expansion, with GAAP diluted EPS up 26.83% and GAAP operating income up 23.86% | |
| UNHUnitedHealth Group Incorporated | 9 | +0.4% | UnitedHealth Group reported adjusted earnings per share of $6.38 against $4.08 a year ago while total revenues of $112 billion were largely consistent with the prior year, as deliberate Medicare Advantage membership repositioning offset underlying premium growth |
Oscar Health grew second-quarter revenue 70% year-over-year to $4.9 billion as membership rose 46% to 2.96 million, and earnings from operations swung to $389 million, a $619 million improvement, with net income of $362 million
The Cigna Group delivered total revenues of $71.7 billion and adjusted EPS of $7.78, with both Evernorth and Cigna Healthcare coming in ahead of expectations
Centene reported $44.4 billion in premium and service revenue and adjusted diluted earnings per share of $2.51, with the consolidated health benefits ratio falling to 89.6% from 93% a year earlier
| Company | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| OSCR | 9 | 5 | 6 | 9 | 9 | 10 |
| CI | 7 | 6 | 6 | 7 | 8 | 8 |
| CNC | 9 | 3 | 7 | 6 | 9 | 9 |
| CVS | 9 | 8 | 9 | 7 | 9 | 9 |
| ELV | 6 | 4 | 6 | 4 | 7 | 5 |
| HUM | 6 | 6 | 5 | 6 | 7 | 8 |
| UNH | 3 | 2 | 4 | 5 | 7 | 9 |
CVS Health delivered a broad-based beat, with revenue up 7.26% to over $106 billion and GAAP operating income up 97.5% year over year as every operating segment grew earnings
Elevance Health delivered adjusted diluted EPS of $7.45, ahead of its outlook, and raised full-year 2026 adjusted EPS guidance to at least $27 on favorable Medicare Advantage and individual ACA benefit-expense performance and disciplined execution
Humana grew GAAP revenue 26.18% year over year on membership expansion, with GAAP diluted EPS up 26.83% and GAAP operating income up 23.86%
UnitedHealth Group reported adjusted earnings per share of $6.38 against $4.08 a year ago while total revenues of $112 billion were largely consistent with the prior year, as deliberate Medicare Advantage membership repositioning offset underlying premium growth
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Mike Ha | Robert W. Baird | 17 questions · 0% challenging |
| Jessica Tassan | Piper Sandler | 16 questions · 0% challenging |
| Jon Yong | UBS | 16 questions · 0% challenging |
| Steve Baxter | Wells Fargo | 13 questions · 15% challenging |
| Andrew Mok | Barclays | 12 questions · 8% challenging |
| Josh Raskin | Nephron Research | 10 questions · 10% challenging |
| Scott Fidel | Goldman Sachs | 8 questions · 0% challenging |
| John Ransom | Raymond James | 7 questions · 14% challenging |
| Raj Kumar | Stephens | 6 questions · 0% challenging |
| Craig Jones | Bank of America | 6 questions · 17% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Robert W. Baird | 1 analyst | 17 questions · 0% challenging |
| Piper Sandler | 1 analyst | 16 questions · 0% challenging |
| UBS | 1 analyst | 16 questions · 0% challenging |
| Bank of America | 4 analysts | 14 questions · 14% challenging |
| Wells Fargo | 1 analyst | 13 questions · 15% challenging |
| Barclays | 1 analyst | 12 questions · 8% challenging |
| Raymond James | 2 analysts | 11 questions · 18% challenging |
| Nephron Research | 1 analyst | 10 questions · 10% challenging |